Chronic Pain Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Chronic Pain pipeline constitutes 10+ key companies continuously working towards developing 10+ Chronic Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Chronic Pain Overview
Chronic pain is long standing pain that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. Chronic pain is longer in duration. It can be constant or intermittent. For example, headaches can be considered chronic pain when they continue over many months or years - even if the pain isn't always present.

"Chronic Pain Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Pain Market.

The Chronic Pain Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Pain Pipeline Report: https://www.delveinsight.com/report-store/chronic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

• Companies across the globe are diligently working toward developing novel Chronic Pain treatment therapies with a considerable amount of success over the years. Chronic Pain Key players such as - Pfizer, Regeneron/Teva Pharmaceuticals/Mitsubishi Tanabe Pharma Corporation, ABBVie, Stayble Therapeutics, Aptinyx, Lateral Pharma, Samumed, Sorrento Therapeutics, Ampio Pharmaceuticals, Semnur Pharmaceuticals, Braeburn Pharmaceuticals/Camurus, Taiwan Liposome Company, Centrexion Therapeutics, Biogen, Allodynic Therapeutics, Lexicon Pharmaceuticals, Gruenthal/Mesoblast, Eli Lilly and Company, Regenacy Pharmaceuticals, Algiax Pharmaceuticals, Bayer, Vertex Pharmaceuticals, Syntrix Biosystems, Neurofix Pharma, MiMedx, and others, are developing therapies for the Chronic Pain treatment
• Chronic Pain Emerging therapies such as - Tanezumab, Fasinumab/REGN475, Atogepant, STA363, NYX-2925, LAT8881, LY-3451838, Lorecivivint/SM04690, Resiniferatoxin/MCP-101, Ampion, SP-102/ Semdexa, CAM2038, TLC599, CNTX-4975, Vixotrigine/BIIB074, ALLOD-2, LX9211, LY3556050, Rexlemestrocel/MPC-06-ID, LY3016859, Ricolinostat/ACY-1215, AP-325, BAY1817080/Eliapixant, VX-150, Omnitram/Desmetramad0l, NFX88, AminoFix/dHACM, and others are expected to have a significant impact on the Chronic Pain market in the coming years.
• In August 2020, Biosplice Therapeutics initiated a long-term extension study evaluating the safety and efficacy of Lorecivivint in subjects with osteoarthritis of the knee
• In September 2021, Biosplice Therapeutics and Haisco Pharmaceutical Group Co., Ltd. announced the execution of a licensing agreement that grants Haisco the right to develop and exclusively commercialize lorecivivint (SM04690) for the treatment of knee osteoarthritis ("OA") and other musculoskeletal conditions in China

Chronic Pain Pipeline Therapeutics Assessment
• Chronic Pain Assessment by Product Type
• Chronic Pain By Stage and Product Type
• Chronic Pain Assessment by Route of Administration
• Chronic Pain By Stage and Route of Administration
• Chronic Pain Assessment by Molecule Type
• Chronic Pain by Stage and Molecule Type

DelveInsight's Chronic Pain Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Chronic Pain Drugs Under Different Phases of Clinical Development Include:
• RBM-010: Ribomic
• BRM521: BRIM Biotechnology
• ORTD 1: Oryn Therapeutics
• GSK 3858279: GlaxoSmithKline
• PPV 06: Peptinov
• FURESTEM-RA: Kangstem Biotech
• Autologous Adiposederived Stem Cells: Celltex Therapeutics
• QR 052: Wuhan Createrna Science and Technology
• AP1189: Synact Pharma
• OLP 1002: OliPass Corporation
• SEL 212: Selecta Biosciences
• MabionCD20: Mabion SA

Get a Free Sample PDF Report to know more about Chronic Pain Pipeline Assessment- https://www.delveinsight.com/sample-request/chronic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Pain Pipeline Analysis:
The Chronic Pain pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Chronic Pain treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Pain Treatment.
• Chronic Pain key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Pain market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Chronic Pain product details are provided in the report. Download the Chronic Pain pipeline report to learn more about the emerging Chronic Pain therapies at:
https://www.delveinsight.com/sample-request/chronic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Pain Pipeline Market Drivers
• Increasing prevalence of various types of chronic pain, such as lower back pain, severe headache or migraine pain, and facial pain
• Growing geriatric population across the world

Chronic Pain Pipeline Market Barriers
• Addiction and toxicity associated with the drugs
• High cost associated with the treatment

Scope of Chronic Pain Pipeline Drug Insight
• Coverage: Global
• Key Chronic Pain Companies: Pfizer, Regeneron/Teva Pharmaceuticals/Mitsubishi Tanabe Pharma Corporation, ABBVie, Stayble Therapeutics, Aptinyx, Lateral Pharma, Samumed, Sorrento Therapeutics, Ampio Pharmaceuticals, Semnur Pharmaceuticals, Braeburn Pharmaceuticals/Camurus, Taiwan Liposome Company, Centrexion Therapeutics, Biogen, Allodynic Therapeutics, Lexicon Pharmaceuticals, Gruenthal/Mesoblast, Eli Lilly and Company, Regenacy Pharmaceuticals, Algiax Pharmaceuticals, Bayer, Vertex Pharmaceuticals, Syntrix Biosystems, Neurofix Pharma, MiMedx, and others
• Key Chronic Pain Therapies: Tanezumab, Fasinumab/REGN475, Atogepant, STA363, NYX-2925, LAT8881, LY-3451838, Lorecivivint/SM04690, Resiniferatoxin/MCP-101, Ampion, SP-102/ Semdexa, CAM2038, TLC599, CNTX-4975, Vixotrigine/BIIB074, ALLOD-2, LX9211, LY3556050, Rexlemestrocel/MPC-06-ID, LY3016859, Ricolinostat/ACY-1215, AP-325, BAY1817080/Eliapixant, VX-150, Omnitram/Desmetramad0l, NFX88, AminoFix/dHACM, and others
• Chronic Pain Therapeutic Assessment: Chronic Pain current marketed and Chronic Pain emerging therapies
• Chronic Pain Market Dynamics: Chronic Pain market drivers and Chronic Pain market barriers

Request for Sample PDF Report for Chronic Pain Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/chronic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Chronic Pain Report Introduction
2 Chronic Pain Executive Summary
3 Chronic Pain Overview
4 Chronic Pain- Analytical Perspective In-depth Commercial Assessment
5 Chronic Pain Pipeline Therapeutics
6 Chronic Pain Late Stage Products (Phase II/III)
7 Chronic Pain Mid Stage Products (Phase II)
8 Chronic Pain Early Stage Products (Phase I)
9 Chronic Pain Preclinical Stage Products
10 Chronic Pain Therapeutics Assessment
11 Chronic Pain Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Chronic Pain Key Companies
14 Chronic Pain Key Products
15 Chronic Pain Unmet Needs
16 Chronic Pain Market Drivers and Barriers
17 Chronic Pain Future Perspectives and Conclusion
18 Chronic Pain Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Chronic Pain drugs and therapies- https://www.delveinsight.com/sample-request/chronic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Chronic Pain Market https://www.delveinsight.com/report-store/chronic-pain-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Chronic Pain-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Chronic Pain Epidemiology https://www.delveinsight.com/report-store/chronic-pain-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Chronic Pain Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast - 2027' report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Basal Cell Carcinoma (Basal Cell Epithelioma) Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.